Table 1.
DUBs and their inhibitors in cancer therapeutics
| DUB | Inhibitor(s) | Disease Indication | Stage of development | References |
|---|---|---|---|---|
| USP1 | ML323, Pimozide | Oncology | Preclinical | (50) |
| USP2 | ML364 | Inflammation | Preclinical | (50) |
| USP4 | Vialinin A | Inflammation and oncology | Preclinical | (51, 52) |
| USP5 | WP1130 | |||
| USP7 | ADC-01, ADC-03 | Oncology, Immuno-oncology | Preclinical | (53) |
| HBX41108 | Oncology, Immuno-oncology | Preclinical | (54, 55) | |
| P5091 | Oncology, Immuno-oncology | Preclinical | (56) | |
| P22077 | Oncology, Immuno-oncology | Preclinical | (56) | |
| USP8 | 9-(Ethoxyimino)-9H-indeno (1,2-b) pyra-zine-2,3-dicarbonitrile | Oncology | Preclinical | (56) |
| USP9X | WP1130 | Oncology | Preclinical | (57) |
| USP10 and USP13 | Spautin 1 | Inflammation | Preclinical | (57) |
| USP11 | Mitoxantrone | Oncology | Preclinical | (58) |
| USP14 | 1U1, b-AP15, VLX1570, wp1130 | Neurodegeneration | Preclinical | (59) |
| USP20 | GSK2643943A | Oncology | Preclinical | (60) |
| USP30 | 15-oxospiramilactone | Neurodegeneration | Preclinical | (61) |
| USP47 | P5091 | Cancer | Preclinical | (56) |
| UCH37 | WP1130 | Cancer | Preclinical | (57) |
| UCHL5 | b-AP15 | Neurology | Preclinical | (62) |
| UCHL1 | LDN-57444 | Cancer | Preclinical | (63) |
| UCHL3 | LDN-57444 | Cancer | Preclinical | (64) |
| UCHL5 | TCID, b-AP15 | Cancer | Preclinical | (62, 65) |
| UCH37 | WP1130 | Cancer | Preclinical | (57) |